AstraZeneca’s Plan To Spur Brilinta Sales Is On Track, CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Plans to jumpstart growth of Brilinta are working, AstraZeneca said during the company’s second quarter sales and earnings call Aug. 1. Investors may not see the results until the end of the year, however.
You may also be interested in...
A Closer Look: China’s Pharmaceutical Bribery Scandal Continues To Spread
Sanofi is the latest company to feel the heat after an anonymous whistleblower alleged that Chinese employees bribed doctors to prescribe Avapro and Avalide. PharmAsia News takes a closer look at the latest developments in a fast-moving scandal that has engulfed GSK and now threatens others.
AstraZeneca’s “Smart Risks” Include Sharing FibroGen’s Anemia Compound With Astellas
The British pharma continues to build its cardiovascular and metabolic pipeline to slow its dive off the patent cliff; in FibroGen’s FG-4592, it sees a potential strong seller in regions where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.